Interstitial lung disease following certolizumab pegol

Rheumatology

Volumn 51, Issue 3, 2012, Pages 578-580

  Pearce, Fiona ^a   Johnson, Simon R ^b   Courtney, Philip ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALENDRONIC ACID; AMOXICILLIN; CERTOLIZUMAB PEGOL; CLARITHROMYCIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; LANSOPRAZOLE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; SIMVASTATIN; TOLTERODINE;

ABNORMAL RESPIRATORY SOUND; AGED; ARTERIAL GAS; BLOOD OXYGEN TENSION; BODY TEMPERATURE; BREATHING RATE; BRONCHOSCOPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DISEASE DURATION; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FUNGAL COLONIZATION; FUNGAL DETECTION; HOME CARE; HUMAN; INJECTION SITE REACTION; INTERSTITIAL LUNG DISEASE; LETTER; LUNG AUSCULTATION; LUNG LAVAGE; LUNG LOBE; OXYGEN SATURATION; OXYGEN THERAPY; PNEUMOCYSTIS JIROVECI; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; THORAX RADIOGRAPHY; TRANSBRONCHIAL BIOPSY; TREATMENT DURATION;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COMBINED MODALITY THERAPY; DYSPNEA; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; LUNG DISEASES, INTERSTITIAL; OXYGEN INHALATION THERAPY; POLYETHYLENE GLYCOLS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84857526103     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker309     Document Type: Letter

References (9)

1. European Medicines Agency. Certolizumab pegol: summary of product characteristics http://www.ema. europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001037/WC500069763.pdf (23 May 2011, date last accessed).
2. NICE Technology Appraisal Guidance 186. Certolizumab pegol for the treatment of rheumatoid arthritis. London, 2010. http://www.nice.org.uk/nicemedia/live/12808/47544/47544.pdf (23 May 2011, date last accessed).
3. Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum 2011. Advance Access published 28 January 2011, doi:10.1016/j.semarthrit.2010.11.002.
4. Ramos-Casals M, Perez-Alvarez R, Perez-de-Lis M, Xaubet A, Bosch X. BIOGEAS Study Group. Pulmonary disorders induced by monoclonal antibodies in patients with rheumatologic autoimmune diseases. Am J Med 2011;124:386-94.
5. Keystone E, Heijde D, Mason D Jr et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, Phase III, multicenter, randomized, double-blind, placebocontrolled, parallel-group study. Arthritis Rheum 2008;58: 3319-29.
6. Smolen J, Landewe RB, Mease P et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. a randomised controlled trial. Ann Rheum Dis 2009;68: 797-804.
7. Fleischmann R, Vencovsky J, van Vollenhoven RF et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2009;68: 805-11.
8. Keystone E, Fleischmann R, Smolen J et al. The efficacy of certolizumab pegol added to methotrexate is sustained over 2 years in the treatment of rheumatoid arthritis. Arthritis Rheum 2009;60(Suppl.):S622.
9. Van vollenhoven R, Smolen J, Schiff M et al. Safety update on certolizumab pegol in patients with active rheumatoid arthritis. Arthritis Rheum 2009;60(Suppl.): S636.